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ABSTRACT
Previous studies have demonstrated that effective cytotoxic T lymphocyte (CTL) responses drive the selection of escape muta-
tions that reduce viral replication capacity (VRC). Escape mutations, including those with reduced VRC, can be transmitted and
accumulate in a population. Here we compared two antiretroviral therapy (ART)-naive HIV clade B-infected cohorts, in Mexico
and Barbados, in which the most protective HLA alleles (HLA-B*27/57/58:01/81:01) are differentially expressed, at 8% and 34%,
respectively. Viral loads were significantly higher inMexico than in Barbados (median, 40,774 versus 14,200; P< 0.0001), and
absolute CD4 T-cell counts were somewhat lower (median, 380/mm3 versus 403/mm3; P 0.007). We tested the hypothesis
that the disparate frequencies of these protective HLA alleles would be associated with a higher VRC at the population level in
Mexico. Analysis of VRC in subjects in each cohort, matched for CD4 T-cell count, revealed that the VRC was indeed higher in
theMexican cohort (mean, 1.13 versus 1.03; P 0.0025). Although CD4 counts were matched, viral loads remained significantly
higher in theMexican subjects (P 0.04). This VRC difference was reflected by a significantly higher frequency in the Barbados
cohort of HLA-B*27/57/58:01/81:01-associated Gag escape mutations previously shown to incur a fitness cost on the virus (P
0.004), a difference between the two cohorts that remained statistically significant even in subjects not expressing these protec-
tive alleles (P 0.01). These data suggest that viral set points and disease progression rates at the population level may be signifi-
cantly influenced by the prevalence of protective HLA alleles such as HLA-B*27/57/58:01/81:01 and that CD4 count-based guide-
lines to initiate antiretroviral therapy may need to be modified accordingly, to optimize the effectiveness of treatment-for-
prevention strategies and reduce HIV transmission rates to the absolute minimum.
IMPORTANCE
Immune control of HIV at an individual level is strongly influenced by the HLA class I genotype. HLA class I molecules mediat-
ing effective immune control, such as HLA-B*27 and HLA-B*57, are associated with the selection of escape mutants that reduce
viral replicative capacity. The escape mutants selected in infected patients can be transmitted and affect the viral load and CD4
count in the recipient. These findings prompt the hypothesis that the frequency of protective alleles in a populationmay affect
viral set points and rates of disease progression in that population. These studies inMexico and Barbados, where the prevalence
rates of protective HLA alleles are 8% and 34%, respectively, support this hypothesis. These data suggest that antiretroviral ther-
apy (ART) treatment-for-prevention strategies will be less successful in populations such as those inMexico, where viral loads
are higher for a given CD4 count. Considerationmay therefore usefully be given to ART initiation at higher absolute CD4 counts
in such populations to optimize the impact of ART for prevention.
It is well established that HLA class I molecules exert strong se-lection pressure on HIV (1–3). Viral escape mutations selected
in response to Gag-specific cytotoxic T lymphocyte (CTL) activity
restricted by protective HLA molecules have fitness costs, as indi-
cated either by in vitro fitness assays or by in vivo reversion follow-
ing transmission to HLA-mismatched individuals (4–18). The
population level frequency of escape variants, including those as-
sociated with reduced viral replicative capacity, appears to be ac-
cumulating, being strongly correlated with the prevalence of the
relevant HLA allele in that population (19). Studies of linked
transmission pairs have shown that CD4 T-cell count and viral
load in a newly infected individual are both strongly related to the
replicative capacity of the transmitted virus (20–23). Together,
these data prompt the hypotheses, first, that the impact of protec-
tive HLA molecules may bring about a reduction in population
level viral fitness as the epidemic progresses, and, second, that
marked differences in viral fitness may be evident in populations
in which protective HLA alleles are expressed at differential levels.
Data supporting these hypotheses have come from Japan. Re-
cent studies have indicated that viral replicative capacity is declin-
ing as the epidemic progresses in that country (24). Previously, it
had been shown that HLA-B*51 was protective early in the Japa-
nese epidemic but is now no longer protective (19). This loss of
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HLA-B*51-associated disease protection has been linked to an
increase in the frequency of the escape mutation RT-135 (I135X)
that abrogates HLA-B*51 binding to the epitope TAFTIPSI (RT-
128 to -135). The HLA-B*51-TAFTIPSI response, in turn, has
been associated with HLA-B*51-mediated immune control of
HIV (25). These data therefore are consistent with the possibility
that viral adaptation to protective HLA molecules may come at the
cost of a decline in population level viral fitness through the accu-
mulation of escape mutants that reduce viral replicative capacity.
To better understand the impact that protective HLA alleles
may have on HIV adaptation at a population level, we compared
two antiretroviral therapy (ART)-naïve HIV clade B-infected co-
horts in which the frequency of protective alleles was substantially
different. A low prevalence of the protective alleles HLA-B*27/57/
58:01/81:01 (26) was observed in the studied Mexican cohort (8%,
n 926), in contrast to the Barbados cohort, exhibiting substan-
tially higher prevalence of these alleles (34%, n 190) (Fig. 1). We
wished to test the hypotheses that first, the population level viral
fitness might be lower in Barbados than in the Mexican cohort,
and second, the frequency of escape mutations associated with
fitness cost driven by HLA-B*27/57/58:01/81:01 is higher in Bar-
bados.
MATERIALS AND METHODS
Study cohorts. The study comprised two adult ART-naive HIV clade
B-infected cohorts (27, 28). The Mexican cohort included 926 individuals
recruited from the Centre for Research in Infectious Diseases, Mexico
City, Mexico. These subjects were enrolled from 2011 to 2012. Viral load
(VL) and CD4 T-cell counts were available for 926 and 919 study sub-
jects, respectively. The median VL of this cohort was 40,774 HIV RNA
copies/ml plasma (interquartile range [IQR], 10,334 to 133,589 c/ml), and
the median CD4 T-cell count was 380 cells/mm3 (IQR, 151 to 592). The
mean age of the cohort was 33 years, and the cohort comprised 20%
females. The Barbados cohort included 190 individuals recruited from
Bridgetown, Barbados. These subjects were enrolled from 2008 to 2010.
VL and CD4 T-cell counts were available for 176 and 171 study subjects,
respectively. The median VL of this cohort was 14,200 HIV RNA cop-
ies/ml plasma (IQR, 2,775 to 59,275), and the median CD4 T-cell count
was 403 cells/mm3 (IQR, 325 to 569). The mean age of the cohort was 38
years, and the cohort comprised 44% females.
Ethical approval for the study was obtained from the Oxford Research
Ethics Committee, the Institutional Bioethics and Science Committee in
Mexico, and the Barbados Ministry of Health. Written informed consent
was obtained from all individuals. In Barbados, viral load determinations
were performed using the Roche Cobas Amplicor (Roche Diagnostics,
Mannheim, Germany) from 2002 to October 2007 and Roche AmpliPrep
and TaqMan 48 Analysers (Roche Diagnostics) from November 2007 to
December 2011. In Mexico, viral loads were initially determined using the
same Roche Ampli-Prep Cobas platform and then, beginning in 2009,
using the Abbott m2000 platform. The Abbott m2000 platform underre-
ports HIV-1 RNA levels compared to the Roche platforms, and therefore
the difference in viral loads observed might if anything be an underesti-
mate (see Discussion) (29, 30). CD4 T-cell counts were determined by
multiparametric flow cytometry (BD).
HLA typing. Four-digit HLA typing of the class I locus for the samples
was performed from genomic DNA as previously described (31) by se-
quence-based typing. Samples from Barbados were typed at the American
Society for Histocompatibility and Immunogenetics (ASHI)-accredited
HLA typing laboratory, University of Oklahoma Health Sciences Center,
Oklahoma City, OK, USA. Samples from Mexico were typed on-site, us-
ing the same method.
Generation of Gag-protease NL4-3 recombinant viruses. Gag-pro-
tease NL4-3 recombinant virus stocks were generated as previously de-
scribed (32) by cotransfection of HIV-inducible, GXR-CEM cells with
Gag-protease-deleted NL4-3 plasmid and clinically derived gag-protease
amplicons from study subjects. The Gag-protease-deleted pNL4-3
(pNL4-3gag-protease) plasmid was kindly provided by Mark Brock-
man, Canada. In brief, viral RNA was isolated from plasma samples using
the QIAamp viral RNA minikit from Qiagen (Valencia, CA). Reverse
transcription-PCR (RT-PCR) was performed using the Superscript III
One-Step RT-PCR kit (Invitrogen, Carlsbad, CA). A second round of PCR
was performed with 100-mer forward and reverse primers complemen-
tary to NL4-3 on either side of Gag-protease, using a HighFidelity Plati-
num Taq polymerase (Invitrogen). For each sample, 10 g of the pNL4-
3gag-protease was linearized by BstE II (New England BioLabs, Ipswich,
MA) digestion and cotransfected with 5 g of purified PCR product of
autologous Gag-protease from patients into 2 106 GXR-CEM reporter
cells in 300 l of R10 medium. Electroporation was carried out at 250 V
and 950 F for 30 ms. The cells were left to rest for 5 min and transferred
to a T25 flask containing 1 106 GXR cells in 10 ml R10 medium. Cells
were then incubated at 37°C. Green fluorescent protein (GFP) expression
was measured every 2 days using a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA) as per the manufacturer’s instructions. Chime-
ric viruses were harvested when15% of GXR-CEM cells were GFP pos-
itive (GFP) and stored at 80°C. Viruses from patients with a CD4
T-cell count between 300 and 500 cells/mm3 were selected for comparison
between cohorts; 45 and 49 chimeric viruses from Mexico and Barbados,
respectively, were studied.
VRC assay. Titration of virus stocks and replication assays were per-
formed as previously described (5, 8), using a multiplicity of infection
(MOI) of 0.003. All assays were carried out in Oxford using aliquots of the
same NL4-3 viral stocks as the control to normalize measurements of viral
replication capacity (VRC). In brief, titration was carried out by the addi-
tion of 400 l of supernatant to 1 106 GXR cells in 1 ml R10 medium.
The percent GFP (GFP%) was measured after 48 h to calculate the MOI.
The VRC assay was then carried out based on titration by infecting 1
106 GXR cells in the same way as described above. The mean slope of
exponential growth from days 2 to 7 was calculated using the semi-log
method in Excel. This was divided by the slope of growth of the wild-type
NL4-3 control included in each assay to generate a normalized measure of
FIG 1 Population frequency of previously described protective class I HLA-B
alleles for HIV clade B chronically infected individuals from Mexico (n 976)
and Barbados (n 190). Prevalence of HLA-B*27, HLA-B*57, HLA-B*58:01,
and HL:A-B*81:01 in Mexico is shown in grey and in Barbados in black.
Fitness Differences Related to Frequency of HLA Alleles
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replication capacity. Replication assays were performed at least in dupli-
cate, and results were averaged.
Sequencing and phylogenetic analysis. Plasma and viral stock se-
quencing was performed as described previously (33). Sequencing was
undertaken using the BigDye Ready Reaction Terminator mix (V3.1)
(Applied Biosystems, United Kingdom). Sequences were analyzed using
Sequencher v4.8 (Gene Codes Corporation) and aligned by SeAl to the
clade B reference strain HXB2. Estimation of founder sequences for the
Mexico and Barbados cohorts was undertaken by the reconstruction of
maximum likelihood phylogenetic trees using the FastML web server
(34).
Statistical analysis. Comparisons between independent groups were
performed using the Mann-Whitney U test for nonnormally distributed
data or using the Student t test for normally distributed data; P values of
	0.05 were considered significant. HLA and viral sequence variant fre-
quencies were compared between groups using Fisher’s exact test. The
relationships between replication capacity and log viral load and CD4
T-cell count were assessed using Spearman’s rank correlation. Analyses
were performed in GraphPad Prism (version 5.03) software (GraphPad
Software, La Jolla, CA).
RESULTS
Lowerviral loadsandhigherCD4T-cell countsobserved in the
Barbados cohort. We first compared the viral loads and CD4
T-cell counts from the two ART-naive clade B virus-infected co-
horts (Barbados, n  190 subjects; Mexico, n  926). Although
the same WHO guidelines for ART initiation have been followed
in the two countries (27, 28), we observed a 2.9-fold difference in
the viral loads (median, 14,200 versus 40,774 RNA copies/ml
plasma in Barbados and Mexico, respectively; P 	 0.0001) and a
more modest difference in the CD4 T-cell counts between co-
horts (median, 403 and 380 cells/mm3 in Barbados and Mexico,
respectively; P 0.007) (see Fig. S1 in the supplemental material).
This difference in viral loads may potentially have arisen from a
variety of causes, including the possibility that ART was initiated
later in the course of infection in Mexico than in Barbados. To
further examine the potential contribution to this result of co-
hort-specific differences in viral replicative capacity, we therefore
matched study subjects from each cohort for CD4 T-cell count
(see Materials and Methods) before determining the VRC in each.
Relationship between viral replicative capacity, CD4 T-cell
counts, and viral load. In several previous studies that have em-
ployed the same method as the one adopted here to measure VRC,
significant associations have consistently been observed between
increasing viral load and increasing VRC and between increasing
CD4 T-cell count and decreasing VRC (8, 24, 32, 35–38). Con-
sistent with these previous studies, in the pooled data from these
two cohorts (n  94), we observed a significant positive correla-
tion between VRC and VL (r 0.25; P 0.02; Fig. 2A). There was
no significant negative correlation between in vitro VRC and
CD4 T-cell counts in these subjects (r  0.14; P  0.19) se-
lected across a relatively narrow range of CD4 count.
Gag-protease chimeric viruses from Barbados have a lower
RC than those fromMexico. To avoid bias caused by disease pro-
gression, VRC was determined in each cohort in a subset of indi-
viduals whose CD4 T-cell counts ranged between 300 and 500
cells/mm3 (mean CD4 T-cell counts, 395 versus 389; P 0.65).
Consistent with our hypothesis, the mean VRC in Mexico was
significantly higher than in Barbados (mean, 1.13 versus 1.03)
(Fig. 3A). Furthermore, although the comparison groups were
closely matched for CD4 T-cell counts, viral loads remained sig-
nificantly higher in the Mexican subset (median, 26,096 versus
13,000; P 0.03) (Fig. 3B).
To determine whether the difference in VRC was observed
only due to the high frequency of individuals expressing protective
alleles in Barbados, we repeated the analysis in the absence of
individuals carrying protective alleles. VRC remained significantly
higher in the Mexican cohort (P  0.01) (Fig. 4A). Additionally,
the median VL remained significantly higher in the Mexico cohort
in the HLA-B*27/57/58:01/81:01-negative individuals (P 0.04)
(Fig. 4B).
AccumulationofGag escapemutationswith viral fitness cost
in Barbados. To determine whether the differences in VRC ob-
served between our study cohorts were associated with the accu-
mulation of any of 8 Gag escape mutations previously shown to
carry a fitness cost, namely, A146X, I147X, A163X, T186X, T242X,
G248X, R264X, and T310X (4, 5, 7–18, 39), we analyzed the Gag
sequences of the viruses included in the VRC measurements. As
FIG 2 Viral replication capacities in Mexico and Barbados cohorts. (A) Correlation of replication capacity of chimeric Gag-Pro/NL4-3 with viral load in study
subjects from both cohorts. (B) Viral replication capacities (VRC) in subjects from Mexico and Barbados. (C) Viral loads in subjects from Mexico and Barbados
in whom VRC was determined.
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anticipated, the frequency of these HLA-B*27/57/58:01/81:01-as-
sociated escape mutations was significantly higher in the viruses
generated from the Barbados cohort (P 0.004 [Fig. 4A]), where
the prevalence of these HLA alleles is substantially higher (Fig. 1).
To determine whether the differences that we observed be-
tween the two cohorts in median viral loads and viral replication
capacity might be related in part to differences in the founder
viruses in Barbados and Mexico, maximum likelihood phyloge-
netic trees were constructed for each cohort with the aim of esti-
mating the founder virus in each case (see Table S1 in the supple-
mental material). They show that the estimated ancestral sequence
for the Barbados and Mexico sequences differed by 7 amino acids
within Gag, including I147L, which is one of the HLA-B*57-asso-
ciated mutants. We therefore excluded the I147L mutant from the
analysis to determine whether the differences in viral replicative
capacity observed in Barbados and Mexico could be explained by
this estimated founder effect. We observed that there was still a
significantly greater number of escape mutants associated with the
protective HLA alleles HLA-B*27/57/58:01/81:01 in the Barbados
sequences analyzed for viral replicative capacity, even in subjects
not expressing these particular protective HLA alleles (mean, 1.5
versus 1.0; P 0.02) (Fig. 4B). Thus, the differential viral replica-
tive capacities observed in Barbados and Mexico are not explained
by HLA-B*27/57/58:01/81:01-associated mutation differences in
founder viruses.
DISCUSSION
The outcome of the transmission of escape mutations is not im-
mediately intuitive. It might be expected that escape mutations
that have a significant cost on VRC would rapidly revert when
selection pressure is lost on transmission to an HLA-mismatched
host (7, 40). However, in practice, reversion in the mismatched
host takes time (41), and in some instances it does not occur at all
(19) if either selection pressure for reversion is too weak (36) or
compensatory mutants are sufficiently effective to reduce the fit-
ness cost of the escape mutant (11, 29). In a population where the
frequency of protective alleles is high, therefore, it is likely that the
viruses transmitted most frequently from individuals expressing
protective alleles will include those with escape mutations that
reduce VRC, and this may result in those variants persisting at
high levels in the population.
The present study examined the potential impact of a high
frequency of protective HLA class I molecules on VRC at a popu-
lation level. We hypothesized that this could lead to the accumu-
lation of escape mutations with a fitness cost at a population level
and therefore to a lower VRC in the population than in a cohort in
FIG 3 Viral replicative capacity and viral load in study cohorts excluding subjects expressing the protective HLA alleles HLA-B57/58:01/81:01/27. (A) Com-
parison of VRC in subjects from Barbados and Mexico lacking the protective HLA allele. (B) Comparison of viral loads in subjects lacking the protective HLA
alleles in each cohort.
FIG 4 Frequency of Gag escape mutants associated with fitness cost in Mexico and Barbados study subjects. (A) Frequency of selected Gag escape variants in
Mexican and Barbados populations (see the text). (B) Frequency of the same variants in the two cohorts but with the analysis limited to individuals not expressing
the protective HLA molecules HLA-B*27/57/58:01/81:01.
Fitness Differences Related to Frequency of HLA Alleles
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which the frequency of protective alleles is lower. We compared
population VRC in two HIV clade B-infected cohorts in Mexico
and Barbados, in which the well-established protective HLA al-
leles, HLA-B*27/57/58:01/81:01, are expressed at very different
frequencies, 8% and 34%, respectively. Consistent with this hy-
pothesis, we observed that Mexican subjects, matched for CD4
count with subjects from the Barbados cohort, on average had
virus exhibiting a higher viral replicative capacity (P  0.0025)
(Fig. 3). This difference remained significant even when patients
with protective alleles were removed from the analysis and even
after taking into account the potential role of founder viruses car-
rying escape mutants. This supports the hypothesis that a rela-
tively low prevalence of protective HLA molecules, such as exists
in Mexico, may contribute to a higher population level viral fit-
ness, while a high prevalence of protective HLA alleles, as in Bar-
bados, may contribute to a low population level viral fitness. These
data are consistent with the observed high viral loads in ART-
naive individuals in Mexico and relatively low viral loads in sub-
jects in Barbados (28). Moreover, significantly higher viral loads
were maintained in the Mexican subjects despite being matched
by CD4 T-cell count to the Barbados subjects and even in those
subjects lacking the protective alleles B*27/57/58:01/81:01.
The differences in VRC observed between the two cohorts were
associated with a higher frequency in the Barbados cohort of Gag
variants previously shown to reduce VRC (B*57-A146X, B*57-
A147X, B*57/58:01-T242N, B*57-G248A, B*27-R264K, and
B*58:01-T310X), and this difference remained significantly
higher in the Barbados cohort even in comparison of subjects not
expressing these protective HLA alleles. For these analyses, we
included HLA-B*27 as well as HLA-B*57/58:01/81:01, although
the prevalence of the former is slightly higher in Mexico, since this
is a well-established protective allele driving the selection of escape
mutants that reduce viral replicative capacity (12, 13). The ob-
served lower viral replicative capacity of viruses in Mexico versus
Barbados therefore occurred in spite of a slightly higher frequency
of HLA-B*27-associated escape mutants in the Mexico cohort
(not shown), and reanalysis of the data having removed the B*27-
associated data did not weaken the statistical significance of the
findings (not shown). These data are consistent with the notions
that escape mutations causing reduced VRC can be transmitted
and remain stable in the population in spite of some fitness cost
and that the higher prevalence of protective alleles in Barbados
may at least in part contribute to the lower population level viral
loads there than those observed in Mexico.
The observation that viral escape mutants are accumulating in
Barbados suggests that the protective effect of alleles such as HLA-
B*57 and HLA-B*58:01 may decline over time, as has been de-
scribed for HLA-B*51 in Japan (19). HLA-B*57:03, the most prev-
alent of the HLA-B*57 alleles in Barbados, remains protective
according to a recent study (30), although in Botswana we have
observed loss of any protective effect mediated by these two closely
related alleles (HLA-B*57/58:01) (R. Payne, P. Matthews, T.
Ndung’u, S. Buus, B. D. Walker, and P. Goulder, unpublished
data). Since the HIV seroprevalence in Botswana has been 20- to
30-fold higher than that in Barbados over the course of the epi-
demic, this factor is likely to have accelerated to a process of viral
adaptation and abrogation of the protective effect of alleles such as
HLA-B*57/58:01. The Mexico and Barbados epidemics arose at a
similar time in the 1980s (42) and have operated at a somewhat
lower adult seroprevalence in Mexico than in Barbados (0.2% in
2012 [www.unaids.org] compared to 0.8 to 1.1% in Barbados).
Earlier studies in Amsterdam, Netherlands (43), suggested that
viral adaptation was resulting in rapid epitope loss within HLA-
B*27/57-restricted CTL epitopes over a 20-year period, in a local-
ity where overall adult seroprevalence has not been dissimilar to
that in Barbados and Mexico. In contrast, recent analyses of viral
adaptation in North America suggest a low rate of viral adaptation
(44). Thus, factors in addition to adult seroprevalence are likely to
play a role in the rate of viral adaptation at the population level.
Potential shortcomings of the study are, first, that the plat-
forms for measuring the viral loads in each cohort were not iden-
tical. In this study, the Abbott m2000 assay was used to measure
viral load in the Mexican cohort starting in 2009, whereas in Bar-
bados and before 2009 in Mexico, viral load measurements were
performed with the Roche Cobas Amplicor and Roche AmpliPrep
and TaqMan 48 Analysers. Viral load comparisons have shown
overall strong agreement between these platforms; however, viral
loads were reported consistently lower by the Abbott m2000 assay
(45, 46). So, in our data set the viral load results in the Mexican
cohort may in fact have been underestimated using the Abbott
m2000 assay, and the differences between the two cohorts may in
reality be greater than those observed. Second, it is possible that
ART was initiated earlier in the course of disease in the Barbados
cohort, which would provide an alternative explanation for the
observed higher viral loads in Mexico. However, in fact the poli-
cies for ART initiation in both countries have followed WHO
recommendations, and the CD4T-cell counts of the two cohorts
were not greatly dissimilar (median, 380/mm3 versus 403/mm3).
Furthermore, even once CD4 counts were matched, VRC was still
significantly higher in the Mexican subjects.
A second shortcoming of the study is that we are measuring the
replicative capacity of chimeric viruses that incorporate the Gag-
Pro sequence from each study subject into NL4-3 and therefore
any differences in replication resulting from changes to viral se-
quence elsewhere in the genome are not taken into account by this
assay.
The data presented in the study are the first suggesting that a
high frequency of protective alleles can shape viral evolution suf-
ficiently to generate an alteration in VRC at a population level, in
association with the accumulation of a higher number of HLA-
associated Gag escape mutants. The viral set points and disease
progression rates may therefore differ between distinct popula-
tions as a result of the frequency of protective alleles in the respec-
tive populations. In this case, the goal of achieving population
level control of the HIV epidemic through initiation of ART at
specific CD4 counts (currently at CD4 counts of 500/mm3) as
recommended by the WHO is likely to be more problematic in
some populations than others. On the basis that HIV transmission
risk is related to viral load (47), consideration might therefore
usefully be given to initiating ART at higher CD4T-cell counts in
some populations than in others to optimize the impact of ART
treatment for prevention.
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